ALung Technologies Inc. has raised a $10 million series B round in preparation for a product launch of its Hemolung oxygen-delivery device in Germany this year, the Pittsburgh Tribune-Review is reporting. MedCity News reported back in December that the medical device company had already raised $6.6 million and filed for the CE Mark. The Hemolung […]
More than 100 angel investors helped ALung Technologies Inc. in Pittsburgh, Pennsylvania, to a $14 million fundraising round, according to Pop City. ALung will use the latest investor capital to pay for ongoing clinical trials of its Hemolung Respiratory Assist System -- a kind of artificial lung that removes carbon dioxide directly from a patient's blood while infusing it with oxygen.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Respiratory-assistance company ALung Technologies Inc. has added $2.8 million in equity to what it hopes will be a $10 million round of investment funding, according to a Securities and Exchange Commission filing. The latest fundraise brings to $6.1 million the amount that ALung has raised since February. The funding includes contributions from 22 investors, according […]
ALung Technologies Inc. has raised $3.3 million in equity as part of an intended $10 million offering. The company is developing a respiratory-assistance system it calls the Hemolung, which delivers oxygen directly into the blood using a catheter into the femoral or jugular vein.
The company is developing its Hemolung System, which delivers oxygen directly into the blood using a catheter into the jugular vein. Later this year it will start a five-patient human trial in India and a 20-patient trial in Germany.